Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses

Neuroscience. 1993 Apr;53(3):673-8. doi: 10.1016/0306-4522(93)90615-m.

Abstract

In rats with a unilateral 6-hydroxydopamine lesion of the dopaminergic nigrostriatal pathway, blockade of muscarinic receptors by scopolamine potentiates the contralateral turning induced by selective dopaminergic D1 agonists (SKF 38393, A 68930), but does not influence the contralateral turning induced by the D2 agonist LY 171555. Studies on the expression of the early gene c-fos as reflected by the immunohistochemical demonstration of the Fos protein, show that administration of scopolamine (5 mg/kg, i.p.) potentiates c-fos expression elicited by SKF 38393 (1.5 mg/kg, s.c.) in the caudate-putamen of the lesioned side. The results indicate that cholinergic transmission is differentially involved in the behavioral expression of D1 versus D2 receptor stimulation in a denervated condition and suggest that blockade of central cholinergic transmission might be useful in improving the antiparkinsonian efficacy of D1 receptor agonists.

MeSH terms

  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / pharmacology
  • Animals
  • Caudate Nucleus / drug effects
  • Caudate Nucleus / physiology
  • Dopamine Agents / pharmacology
  • Ergolines / pharmacology
  • Gene Expression / drug effects
  • Genes, fos / drug effects*
  • Immunohistochemistry
  • Male
  • Muscarinic Antagonists*
  • Oxidopamine / pharmacology
  • Parasympathetic Nervous System / drug effects
  • Parasympathetic Nervous System / physiology
  • Putamen / drug effects
  • Putamen / physiology
  • Quinpirole
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Dopamine D1 / physiology*
  • Receptors, Dopamine D2 / drug effects*
  • Scopolamine / pharmacology
  • Stereotyped Behavior / drug effects*
  • Synaptic Transmission / drug effects

Substances

  • Dopamine Agents
  • Ergolines
  • Muscarinic Antagonists
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • Quinpirole
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
  • Oxidopamine
  • Scopolamine